The Filing Desk

Vir Biotechnology vs Z Squared

Vir Biotechnology VIR · Z Squared ZSQR · Biotechnology

Vir Biotechnology reported revenue of $69 million in fiscal 2025, 49.0 times Z Squared's $1 million in fiscal 2025. Vir Biotechnology had an operating margin of -699.2%, against -956.9% at Z Squared.

Side by side

Vir BiotechnologyZ Squared
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$69M$1M
Revenue growth−7.6%—
Revenue growth a year, last 5 years−2.1%—
Gross margin100.0%86.8%
Operating margin−699.2%−956.9%
Net margin−638.9%−874.3%
Free cash flow−$397M—
Free cash flow margin−578.5%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count1.7%120.0%
Last close$12.21$3.36
P/E at the last close——
Insider trades, last 12 monthssold $8.2 million—
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Vir BiotechnologyZ Squared
Operating margin
Percent of revenue
Vir BiotechnologyZ Squared
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Vir BiotechnologyZ Squared

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Vir Biotechnology and Z Squared pages.